Symbiotec Pharmalab IPO
IPO Key Details
Price Band
₹938 to ₹988
Face Value
₹2 per share
Fresh Issue
15,21,261 shares (agg. up to ₹150 Cr)
Total Issue Size
1,77,86,442 shares (agg. up to ₹1,757 Cr)
Issue Type
Bookbuilding IPO
Exchange
BSE, NSE
Important Dates
IPO Open Date
Mon, Aug 24, 2026
IPO Close Date
Thu, Aug 27, 2026
Allotment Date
Fri, Aug 28, 2026
Listing Date
Tue, Sep 1, 2026
Symbiotec Pharmalab Limited — company overview pending.
About the Company
⚠️ TODO — write from the RHP once uploaded. Do not copy from any website.
Company Strengths
⚠️ TODO — write from the RHP once uploaded.
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
| 1 | Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | 112.50 |
| 2 | General corporate purposes |
Financial Performance
| Period Ended | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
| Assets | 1,780.79 | 1,579.65 | 1,294.79 |
| Total Income | 872.26 | 755.98 | 723.33 |
| Profit After Tax | 109.90 | 96.79 | 100.06 |
| EBITDA | 231.97 | 206.11 | 177.04 |
| NET Worth | 1,158.64 | 821.15 | 720.68 |
| Reserves and Surplus | 1,145.95 | 810.03 | 709.54 |
| Total Borrowing | 387.91 | 540.92 | 247.21 |
| Amount in ₹ Crore |
GMP Today
⚠️ TODO — pull the current GMP figure once available.
IPO Reservation
| Investor Category | Shares |
| QIB | Not more than 50% of the Net Offer |
| Retail | Not less than 35.00% of the Net Offer |
| NII | Not less than 15% of the Net Offer |
Promoter Holding
⚠️ TODO — write from the RHP once uploaded.
Lead Managers
- JM Financial Ltd.
- Avendus Capital Pvt.Ltd.
- Motilal Oswal Investment Advisors Ltd.
- Nomura Financial Advisory & Securities (India) Pvt.Ltd.
Registrar and IPO Status
Registrar: MUFG Intime India Pvt.Ltd.
Key Risk Factors
⚠️ TODO — write from the RHP once uploaded.
Frequently Asked Questions
⚠️ TODO — write from the RHP once uploaded.
Disclaimer
This page is meant only for informational and educational purposes. IPO investments are subject to market risks. Investors should read the DRHP/RHP and final offer document carefully and consult a financial advisor before making any investment decision.